|185.20||+3.78||+2.08%||Vol 319.08K||1Y Perf -21.93%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||237.83||Analyst Rating||Strong Buy 1.40|
|Potential %||28.42||Finscreener Ranking||★+ 43.21|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★+ 43.01|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★ 45.23|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||★★★★+ 55.82|
|Price Range Ratio 52W %||26.87||Earnings Rating||Buy|
|Market Cap||18.39B||Earnings Date||10th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2023|
|Estimated EPS Next Report||2.15|
|EPS Growth Next 5 Years %||11.00|
|Avg. Weekly Volume||577.64K|
|Avg. Monthly Volume||574.26K|
|Avg. Quarterly Volume||538.83K|
STERIS plc (Ireland) (NYSE: STE) stock closed at 185.2 per share at the end of the most recent trading day (a 2.08% change compared to the prior day closing price) with a volume of 319.08K shares and market capitalization of 18.39B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 13000 people. STERIS plc (Ireland) CEO is Daniel A. Carestio.
The one-year performance of STERIS plc (Ireland) stock is -21.93%, while year-to-date (YTD) performance is 0.28%. STE stock has a five-year performance of 106.49%. Its 52-week range is between 159.21 and 255.9325, which gives STE stock a 52-week price range ratio of 26.87%
STERIS plc (Ireland) currently has a PE ratio of -1 597.90, a price-to-book (PB) ratio of 3.30, a price-to-sale (PS) ratio of 5.34, a price to cashflow ratio of 25.60, a PEG ratio of 2.32, a ROA of -0.08%, a ROC of 0.51% and a ROE of -0.14%. The company’s profit margin is -4.39%, its EBITDA margin is 16.20%, and its revenue ttm is $3.57 Billion , which makes it $35.74 revenue per share.
Of the last four earnings reports from STERIS plc (Ireland), there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $2.15 for the next earnings report. STERIS plc (Ireland)’s next earnings report date is 10th May 2023.
The consensus rating of Wall Street analysts for STERIS plc (Ireland) is Strong Buy (1.4), with a target price of $237.83, which is +28.42% compared to the current price. The earnings rating for STERIS plc (Ireland) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
STERIS plc (Ireland) has a dividend yield of 0.99% with a dividend per share of $1.88 and a payout ratio of 33.00%.
STERIS plc (Ireland) has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.16, ATR14 : 4.65, CCI20 : 21.23, Chaikin Money Flow : -0.06, MACD : -2.95, Money Flow Index : 39.34, ROC : 2.72, RSI : 49.98, STOCH (14,3) : 88.03, STOCH RSI : 1.00, UO : 54.64, Williams %R : -11.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of STERIS plc (Ireland) in the last 12-months were: Andrew Xilas (Option Excercise at a value of $0), Cary L Majors (Sold 2 750 shares of value $526 758 ), J. Adam Zangerle (Option Excercise at a value of $543 840), J. Adam Zangerle (Sold 10 659 shares of value $2 589 795 ), Karen L. Burton (Option Excercise at a value of $308 280), Karen L. Burton (Sold 4 000 shares of value $984 000 ), Michael J. Tokich (Sold 8 000 shares of value $2 000 000 ), Richard C. Breeden (Option Excercise at a value of $308 670)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Steris PLC is a medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Its operating segment includes Healthcare, Applied Sterilization Technologies, and Life Sciences. The company generates maximum revenue from Healthcare segment.
CEO: Daniel A. Carestio
Telephone: +1 440 354-2600
Address: 5960 Heisley Road, Mentor 44060, OH, US
Number of employees: 13 000
Wed, 15 Feb 2023 05:30 GMT Analysts Offer Insights on Healthcare Companies: Steris (STE), Benitec Biopharma (BNTC) and Bicycle Therapeutics (BCYC)- TipRanks. All rights reserved.
Thu, 09 Feb 2023 16:31 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Molina Healthcare (MOH), Steris (STE) and Catalent (CTLT)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.